Hikma Advances Epinephrine Nasal Spray With Multi-market Regulatory Filings

Hikma Pharmaceuticals said U.S., European and UK regulators have accepted for review its submissions for an epinephrine nasal spray intended to treat allergic reactions, including anaphylaxis. The milestone advances a potential needle-free alternative in emergency allergy treatment, though approval timing and commercial prospects remain uncertain.